CY1106799T1 - Ανταγωνιστες των cxcr3-συνδεσης cxc χημειοκινων - Google Patents
Ανταγωνιστες των cxcr3-συνδεσης cxc χημειοκινωνInfo
- Publication number
- CY1106799T1 CY1106799T1 CY20071100857T CY071100857T CY1106799T1 CY 1106799 T1 CY1106799 T1 CY 1106799T1 CY 20071100857 T CY20071100857 T CY 20071100857T CY 071100857 T CY071100857 T CY 071100857T CY 1106799 T1 CY1106799 T1 CY 1106799T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cxcr3
- binding
- diseases
- binding components
- cxc chemokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
Abstract
Καινοτόμοι ανταγωνιστές CΧCR3-σύνδεσης CXC χημειοκινών, και συγκεκριμένα του ανθρώπινου CΧCL11, μπορούν να ληφθούν με τη δημιουργία προϊόντων μετάλλαξης των χημειοκινών αυτού του τύπου, στις οποίες η σύνδεση με γλυκοσαμινογλυκάνες (GΑGs) εμποδίζεται από μη συντηρητικές υποκαταστάσεις των αμινοξέων που εμπλέκονται σε αυτή την αλληλεπίδραση. Οι ενώσεις που παρασκευάζονται σε συμφωνία με την παρούσα εφεύρεση μπορούν να χρησιμοποιηθούν για να αποκλείσουν τη δραστηριότητα των CΧCR3-σύνδεσης CΧC χημειοκινών σε κύτταρα που εκφράζουν CΧCR3, παρέχοντας έτσι θεραπευτικές συνθέσεις για χρήση στη θεραπεία ή την πρόληψη νόσων που σχετίζονται με εκτεταμένη μετανάστευση ενεργοποιημένων κυττάρων Τ, όπως απόρριψης μοσχεύματος και αυτοάνοσων νόσων, και νόσων που απαιτούν την αύξηση της αγγείωσης. όπως ισχαιμική καρδιακή νόσος.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02100697 | 2002-06-12 | ||
EP03759978A EP1515990B1 (en) | 2002-06-12 | 2003-06-03 | Antagonists of cxcr3-binding cxc chemokines |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106799T1 true CY1106799T1 (el) | 2012-10-24 |
Family
ID=29724537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100857T CY1106799T1 (el) | 2002-06-12 | 2007-06-28 | Ανταγωνιστες των cxcr3-συνδεσης cxc χημειοκινων |
Country Status (16)
Country | Link |
---|---|
US (1) | US7541435B2 (el) |
EP (1) | EP1515990B1 (el) |
JP (1) | JP4394569B2 (el) |
AR (1) | AR040200A1 (el) |
AT (1) | ATE359297T1 (el) |
AU (1) | AU2003255505B2 (el) |
CA (1) | CA2489298C (el) |
CY (1) | CY1106799T1 (el) |
DE (1) | DE60313168T2 (el) |
DK (1) | DK1515990T3 (el) |
ES (1) | ES2282666T3 (el) |
IL (1) | IL165727A (el) |
NO (1) | NO332309B1 (el) |
PT (1) | PT1515990E (el) |
SI (1) | SI1515990T1 (el) |
WO (1) | WO2003106488A2 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7964194B2 (en) * | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
AU2005219322B2 (en) * | 2004-03-09 | 2008-09-18 | Kyoto University | Pharmaceutical Composition Comprising CXCR3 Inhibitor |
ITFI20040243A1 (it) * | 2004-11-25 | 2005-02-25 | Paola Romagnani | Metodo diagnostico per la previsione di rigetto di organo trapiantato |
WO2006069449A1 (en) * | 2004-12-29 | 2006-07-06 | The University Of British Columbia | Chemokine receptor-independent immunomodulatory and anti-proliferative activity |
JP2008545396A (ja) * | 2005-05-18 | 2008-12-18 | インターミューン インコーポレイテッド | 非天然ケモカイン受容体リガンドおよびこれらの使用方法 |
EP2136832B1 (en) | 2007-03-26 | 2015-09-02 | General Regeneratives Limited | Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
EP2164508B1 (en) * | 2007-06-04 | 2014-01-08 | Rappaport Family Institute for Research in the Medical Sciences | Agents for the treatment of inflammatory diseases and methods of using same |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
JP2018521959A (ja) * | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Btlaアゴニスト抗体を用いた免疫応答のモジュレーション |
EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
GB202214951D0 (en) * | 2022-10-11 | 2022-11-23 | Univ London Queen Mary | CXC receptor ligands |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
US5656724A (en) * | 1994-10-26 | 1997-08-12 | Repligen Corporation | Chemokine-like proteins and methods of use |
US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
US6140064A (en) * | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
US5977334A (en) * | 1997-09-11 | 1999-11-02 | The Cleveland Clinic Foundation | DNA encoding a chemokine, Beta R1, comprising the Beta R1 promoter |
US20020018776A1 (en) * | 2000-04-14 | 2002-02-14 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CXCR3 function |
AU2001273387A1 (en) * | 2000-07-12 | 2002-01-21 | Gryphon Therapeutics, Inc. | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
CA2430401A1 (en) | 2000-12-01 | 2002-06-06 | Schering Corporation | Uses of mammalian genes and related reagents |
-
2003
- 2003-06-03 DE DE60313168T patent/DE60313168T2/de not_active Expired - Lifetime
- 2003-06-03 EP EP03759978A patent/EP1515990B1/en not_active Expired - Lifetime
- 2003-06-03 ES ES03759978T patent/ES2282666T3/es not_active Expired - Lifetime
- 2003-06-03 PT PT03759978T patent/PT1515990E/pt unknown
- 2003-06-03 CA CA2489298A patent/CA2489298C/en not_active Expired - Fee Related
- 2003-06-03 SI SI200330798T patent/SI1515990T1/sl unknown
- 2003-06-03 AT AT03759978T patent/ATE359297T1/de active
- 2003-06-03 US US10/517,726 patent/US7541435B2/en not_active Expired - Fee Related
- 2003-06-03 JP JP2004513319A patent/JP4394569B2/ja not_active Expired - Fee Related
- 2003-06-03 DK DK03759978T patent/DK1515990T3/da active
- 2003-06-03 AU AU2003255505A patent/AU2003255505B2/en not_active Ceased
- 2003-06-03 WO PCT/EP2003/050211 patent/WO2003106488A2/en active IP Right Grant
- 2003-06-11 AR ARP030102092A patent/AR040200A1/es active IP Right Grant
-
2004
- 2004-12-12 IL IL165727A patent/IL165727A/en not_active IP Right Cessation
-
2005
- 2005-01-12 NO NO20050162A patent/NO332309B1/no not_active IP Right Cessation
-
2007
- 2007-06-28 CY CY20071100857T patent/CY1106799T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO332309B1 (no) | 2012-08-20 |
EP1515990A2 (en) | 2005-03-23 |
ES2282666T3 (es) | 2007-10-16 |
JP4394569B2 (ja) | 2010-01-06 |
CA2489298C (en) | 2012-09-11 |
ATE359297T1 (de) | 2007-05-15 |
JP2006511200A (ja) | 2006-04-06 |
WO2003106488A2 (en) | 2003-12-24 |
AU2003255505B2 (en) | 2009-01-08 |
US7541435B2 (en) | 2009-06-02 |
EP1515990B1 (en) | 2007-04-11 |
WO2003106488A3 (en) | 2004-04-15 |
NO20050162L (no) | 2005-01-12 |
IL165727A (en) | 2010-05-17 |
US20060204498A1 (en) | 2006-09-14 |
CA2489298A1 (en) | 2003-12-24 |
PT1515990E (pt) | 2007-05-31 |
DE60313168D1 (de) | 2007-05-24 |
DE60313168T2 (de) | 2007-12-20 |
DK1515990T3 (da) | 2007-06-11 |
AR040200A1 (es) | 2005-03-16 |
SI1515990T1 (sl) | 2007-08-31 |
IL165727A0 (en) | 2006-01-15 |
AU2003255505A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106799T1 (el) | Ανταγωνιστες των cxcr3-συνδεσης cxc χημειοκινων | |
Javed et al. | Cytokine profile in the gingival crevicular fluid of rheumatoid arthritis patients with chronic periodontitis | |
CY1107281T1 (el) | Παραγωγα τροπανιου υποκατεστημενα με ιδιδαζοπυριδινη με ενεργοτητα ανταγωνιστη ccr5 υποδοχεα για τη θεραπεια hiv και φλεγμονης | |
NO20052272L (no) | CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom | |
TR199900318T2 (xx) | IL-8 resept�r antagonistleri. | |
NO20075560L (no) | Purin og imidazopyridin derivater for immunsuppresjon | |
ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
BRPI0513477A (pt) | composições e processos de uso de proteìna 4 semelhante a angiotensina | |
ECSP104578A (es) | Derivados de indolilmaleimida como inhibidores de proteína de cinasa c | |
EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
MX9205985A (es) | Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen. | |
CY1115580T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης | |
TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
BRPI0410495A (pt) | composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento | |
BR0309238A (pt) | Antagonistas de proteìnas mcp | |
BRPI0415290A (pt) | uso terapêutico de variantes de quimiocina | |
MX9307983A (es) | Derivados de aminoacidos de heterociclos como inhibidores de la proteina quinasa c. | |
ATE286074T1 (de) | Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten | |
ES2128348T3 (es) | Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular. | |
CY1112015T1 (el) | ΕΝΙΣΧΥΤΕΣ ΤΗΣ ΜΕΤΑΓΡΑΦΗΣ ΤΗΣ eNOS ΓΙΑ ΝΑ ΧΡΗΣΙΜΟΠΟΙΗΘΟΥΝ ΣΤΗΝ ΚΥΤΤΑΡΙΚΗ ΘΕΡΑΠΕΙΑ ΙΣΧΑΙΜΙΚΩΝ ΚΑΡΔΙΑΚΩΝ ΝΟΣΩΝ | |
ATE482229T1 (de) | Modifizierte allergene der ns-ltps-familie enthaltende fusionsproteine, deren verwendung und pharmazeutische zusammensetzung, die diese verbindungen enthält | |
DK1299541T3 (da) | Fremgangsmåde til udvinding og anvendelse af nye humane defensiner som biologisk aktive proteiner til behandling af infektioner og andre sygdomme | |
CY1106540T1 (el) | Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες | |
EA009044B1 (ru) | Вещество, обладающее антидепрессивной активностью |